Drug Delivery CDMO Services Corporate Milestones

Who are the Market Top Companies and What are Their Offerings?

Recent Developments in the Market

• In April 2026, tentative approval from the U.S. FDA for an Abbreviated New Drug Application (ANDA) for a generic version of Ozempic semaglutide injection was announced by the collaboration between OneSource Specialty Pharma, Orbicular Pharmaceutical Technologies, and a U.S.-based front-end partner. In this collaboration, OneSource will act as the contract development and manufacturing organisation partner (CDMO).
• In February 2026, successful participation in Vitafoods India 2026, which is the country's premier nutraceutical and wellness exhibition, was announced by Avery Pharmaceuticals Pvt. Ltd. The company will exhibit its contract manufacturing development services for orally dissolving strips and cutting-edge solutions in drug delivery.

Market Value Chain Analysis

R&D

• The R&D of the drug delivery CDMO services focuses on the development of automated biomanufacturing and next-generation bioavailability.
• Key players: Lonza and Evonik.

Packaging and Serialization

• The packaging and serialization of the drug delivery CDMO services involve the use of automated secondary packing along with the track-and-trace technology.
• Key players: Vetter Pharma, Sharp Service, and Recipharm.

Patient Support and Services

• The patient-centric device design, training devices, and onboarding solutions are provided in the patient support and services of the drug delivery CDMO services.
• Key players: Aptar Pharma, West Pharmaceutical Services.

Market Growth

The global drug delivery CDMO services market size was estimated at USD 246 billion in 2025 and is predicted to increase from USD 268.39 billion in 2026 to approximately USD 587.74 billion by 2035, expanding at a CAGR of 9.1% from 2026 to 2035.